A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer

Stopped early · Phase 3

Conditions studied: Colorectal Neoplasms

In brief

The purpose of this study is to evaluate relatlimab in combination with nivolumab, administered as a fixed-dose combination (nivolumab-relatlimab FDC, also referred to as BMS-986213) for the treatment of non-microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC) participants who failed at least 1 but no more than 4 prior lines of therapy for metastatic disease.

Key facts

Study ID

NCT05328908

Run by

Bristol-Myers Squibb

People needed

770

Starts

2022-04-28

Expected to finish

2025-07-14

Last updated by the study team

2025-08-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histological confirmed previously treated colorectal cancer with adenocarcinoma histology with metastatic or recurrent unresectable disease at study entry.
• Participants must have:.
• i) progressed during or within approximately 3 months following the last administration of approved standard therapies (at least 1, but not more than 4 prior lines of therapies in the metastatic setting), which must include a fluoropyrimidine, oxaliplatin, irinotecan, an anti-VEGF therapy, and anti-EGFR therapy (if RAS wild-type), if available in the respective country, or;.
• ii) been intolerant to prior systemic chemotherapy regimens if there is documented evidence of clinically significant intolerance despite adequate supportive measures.
• Must have sufficient tumor tissue \& evaluable PD-L1 expression to meet the study requirements.
• Must have measurable disease per RECIST v1.1. Participants with lesions in a previously irradiated field as the sole site of measurable disease will be permitted to enroll provided the lesion(s) have demonstrated clear progression and can be measured accurately.

You may not qualify if…

• Prior treatment with either an immunotherapy or with regorafenib or with TAS-102.
• Untreated central nervous system (CNS) metastases, participants are eligible if CNS metastases have been treated and participants have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment).
• History of refractory hypertension not controlled with anti-hypertensive therapy, myocarditis (regardless of etiology), uncontrolled arrhythmias, acute coronary syndrome within 6 months prior to dosing, Class II congestive heart failure (as per the New York Heart Association Functional Classification), interstitial lung disease/pneumonitis or an active, known or suspected autoimmune disease.
• Confirmed tumor microsatellite instable high/deficient mismatch repair (MSI-H/dMMR) status as per local standard testing; MSI/MMR test results from initial diagnosis are acceptable.
• Other protocol-defined Inclusion/Exclusion criteria apply.

Where it is running

• Local Institution - 0090 — Dijon, France
• Local Institution - 0069 — Bern, Switzerland
• Local Institution - 0044 — Springdale, Arkansas, United States
• Local Institution - 0012 — Los Angeles, California, United States
• Local Institution - 0117 — Norwich, Connecticut, United States
• Local Institution - 0025 — Miami, Florida, United States
• Local Institution - 0031 — Atlanta, Georgia, United States
• Local Institution - 0071 — Boise, Idaho, United States
• Local Institution - 0081 — Fort Wayne, Indiana, United States
• Massachusetts General Hospital, — Boston, Massachusetts, United States
• Local Institution - 0042 — Ann Arbor, Michigan, United States
• Local Institution - 0043 — East Brunswick, New Jersey, United States
• Local Institution - 0009 — Durham, North Carolina, United States
• Local Institution - 0082 — Cincinnati, Ohio, United States
• Local Institution - 0095 — Columbus, Ohio, United States
• Local Institution - 0147 — Philadelphia, Pennsylvania, United States
• Local Institution - 0008 — Charleston, South Carolina, United States
• Local Institution - 0096 — Sioux Falls, South Dakota, United States
• Local Institution - 0127 — Nashville, Tennessee, United States
• Local Institution - 0097 — Fort Worth, Texas, United States
• Local Institution - 0132 — Richmond, Virginia, United States
• Local Institution - 0005 — Madison, Wisconsin, United States
• Local Institution - 0022 — Ciudad Autónoma Buenos Aires, Buenos Aires, Argentina
• Local Institution - 0026 — Ciudad Autónoma Buenos Aires, B, Argentina
• Local Institution - 0017 — Caen, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.